Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects

Neuropharmacology

Volumn 59, Issue 3, 2010, Pages 149-159

  Buckley, Clare E ^a,b,c   Marguerie, Anita ^b,d   Roach, Alan G ^b,e   Goldsmith, Paul ^b,e   Fleming, Angeleen ^a,b,f   Alderton, Wendy K ^b,g   Franklin, Robin J M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b SUMMIT PLC   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Stem Cell Sciences UK Ltd   (United Kingdom)

^e Vastrata Limited   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g CB1 Bio Limited   (United Kingdom)

Author keywords

Multiple sclerosis; Oligodendrocyte; Remyelination; Screening

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANALGESIC AGENT; ANTIAMEBIC AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTIPROTOZOAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA LACTAM ANTIBIOTIC; BIOGENIC AMINE; BUTYROPHENONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; ISOXICAM; LOOP DIURETIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENOTHIAZINE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; UNINDEXED DRUG; VASODILATOR AGENT; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENZYME INHIBITOR; GREEN FLUORESCENT PROTEIN; MYELIN BASIC PROTEIN; NERVE PROTEIN; OLIG2 PROTEIN, ZEBRAFISH; PIROXICAM; ZEBRAFISH PROTEIN;

ARTICLE; CELL LINEAGE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; EMBRYO; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REMYELINIZATION; STRUCTURE ACTIVITY RELATION; ZEBRA FISH; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL EMBRYO; ANIMAL MODEL; CELL COUNT; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; PROCEDURES; SPINAL CORD; TRANSGENIC ANIMAL;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL COUNT; CELL DIFFERENTIATION; DRUG EVALUATION, PRECLINICAL; EMBRYO, NONMAMMALIAN; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GREEN FLUORESCENT PROTEINS; MODELS, ANIMAL; MYELIN BASIC PROTEINS; NERVE TISSUE PROTEINS; OLIGODENDROGLIA; PIROXICAM; SPINAL CORD; ZEBRAFISH; ZEBRAFISH PROTEINS; MYELIN BASIC PROTEIN;

EID: 77954142973     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.04.014     Document Type: Article

References (61)

1. Altman D.G. Practical Statistics for Medical Research 1991, Chapman & Hall/CRC.
2. Bakke O.M., Manocchia M., de Abajo F., Kaitin K.I., Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin. Pharmacol. Ther. 1995, 58:108-117.
3. Bruce C.C., Zhao C., Franklin R.J.M. Remyelination - an effective means of neuroprotection. Horm. Behav. 2010, 57:56-62.
4. Buckley C.E., Goldsmith P., Franklin R.J.M. Zebrafish myelination: a transparent model for remyelination?. Dis. Model. Mech. 2008, 1:221-228.
5. Buckley C.E., Marguerie A., Alderton W.K., Franklin R.J.M. Temporal dynamics of myelination in the zebrafish spinal cord. Glia 2010, 58:802-812.
6. Chan J.R., Phillips L.J., Glaser M. Glucocorticoids and progestins signal the initiation and enhance the rate of myelin formation. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:10459-10464.
7. Coles A.J., Compston D.A., Selmaj K.W., Lake S.L., Moran S., Margolin D.H., Norris K., Tandon P.K. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 2008, 359:1786-1801.
8. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
9. De Nicola A.F., Gonzalez S.L., Labombarda F., Deniselle M.C., Garay L., Guennoun R., Schumacher M. Progesterone treatment of spinal cord injury: effects on receptors, neurotrophins, and myelination. J. Mol. Neurosci. 2006, 28:3-15.
10. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., Lipsky P.E. Cyclooxygenase in biology and disease. FASEB J. 1998, 12:1063-1073.
11. Ghoumari A.M., Ibanez C., El-Etr M., Leclerc P., Eychenne B., OMalley B.W., Baulieu E.E., Schumacher M. Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J. Neurochem. 2003, 86:848-859.
12. Ghoumari A.M., Baulieu E.E., Schumacher M. Progesterone increases oligodendroglial cell proliferation in rat cerebellar slice cultures. Neuroscience 2005, 135:47-58.
13. Giovannoni G., Comi G., Cook S., Rammohan K., Rieckmann P., Soelberg Sorensen P., Vermersch P., Chang P., Hamlett A., Musch B., Greenberg S.J. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:416-426.
14. Guillaume J.C., Roujeau J.C., Chevais M., Albengres E., Revuz J., Touraine R. Lyells syndrome and ectodermosis pluriorificialis during treatment with oxicams: 11 cases. Ann. Dermatol. Venereol. 1985, 112:807-812.
15. Ibanez C., Shields S.A., El-Etr M., Baulieu E.E., Schumacher M., Franklin R.J.M. Systemic progesterone administration results in a partial reversal of the age-associated decline in CNS remyelination following toxin-induced demyelination in male rats. Neuropathol. Appl. Neurobiol. 2004, 30:80-89.
16. Ishikawa T.O., Griffin K.J., Banerjee U., Herschman H.R. The zebrafish genome contains two inducible, functional cyclooxygenase-2 genes. Biochem. Biophys. Res. Commun. 2007, 352:181-187.
17. Jung S.H., Kim S., Chung A.Y., Kim H.T., So J.H., Ryu J., Park H.C., Kim C.H. Visualization of myelination in GFP-transgenic zebrafish. Dev. Dyn. 2010, 239:592-597.
18. Kimmel C.B., Ballard W.W., Kimmel S.R., Ullmann B., Schilling T.F. Stages of embryonic development of the zebrafish. Dev. Dyn. 1995, 203:253-310.
19. Koenig H.L., Schumacher M., Ferzaz B., Thi A.N., Ressouches A., Guennoun R., Jung-Testas I., Robel P., Akwa Y., Baulieu E.E. Progesterone synthesis and myelin formation by Schwann cells. Science 1995, 268:1500-1503.
20. Labombarda F., Gonzalez S.L., Lima A., Roig P., Guennoun R., Schumacher M., de Nicola A.F. Effects of progesterone on oligodendrocyte progenitors, oligodendrocyte transcription factors, and myelin proteins following spinal cord injury. Glia 2009, 57:884-897.
21. Lieschke G.J., Currie P.D. Animal models of human disease: zebrafish swim into view. Nat. Rev. Genet. 2007, 8:353-367.
22. Lin X., Ramamurthy S.K., Le Breton G.C. Thromboxane A receptor-mediated cell proliferation, survival and gene expression in oligodendrocytes. J. Neurochem. 2005, 93:257-268.
23. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J.A., Diab A., Drew P.D., Racke M.K. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol. 2004, 172:5790-5798.
24. Mason J.L., Xuan S., Dragatsis I., Efstratiadis A., Goldman J.E. Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination. J. Neurosci. 2003, 23:7710-7718.
25. Osterhout D.J., Wolven A., Wolf R.M., Resh M.D., Chao M.V. Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase. J. Cell Biol. 1999, 145:1209-1218.
26. Paintlia A.S., Paintlia M.K., Singh I., Singh A.K. IL-4-induced peroxisome proliferator-activated receptor gamma activation inhibits NF-kappaB trans activation in central nervous system (CNS) glial cells and protects oligodendrocyte progenitors under neuroinflammatory disease conditions: implication for CNS-demyelinating diseases. J. Immunol. 2006, 176:4385-4398.
27. Park H.C., Shin J., Appel B. Spatial and temporal regulation of ventral spinal cord precursor specification by Hedgehog signaling. Development 2004, 131:5959-5969.
28. Park H.C., Boyce J., Shin J., Appel B. Oligodendrocyte specification in zebrafish requires notch-regulated cyclin-dependent kinase inhibitor function. J. Neurosci. 2005, 25:6836-6844.
29. Penderis J., Woodruff R.H., Lakatos A., Li W.W., Dunning M.D., Zhao C., Marchionni M., Franklin R.J.M. Increasing local levels of neuregulin (glial growth factor-2) by direct infusion into areas of demyelination does not alter remyelination in the rat CNS. Eur. J. Neurosci. 2003, 18:2253-2264.
30. Pombo P.M., Barettino D., Ibarrola N., Vega S., Rodriguez-Pena A. Stimulation of the myelin basic protein gene expression by 9-cis-retinoic acid and thyroid hormone: activation in the context of its native promoter. Brain Res. Mol. Brain Res. 1999, 64:92-100.
31. Prestwick-Chemical. Prestwick Chemical Library. http://www.prestwickchemical.com.
32. Prieto A., De Barrio M., Perez C., Velloso A., Baeza M.L., Herrero T. Piroxicam-induced erythema multiforme. Contact Dermat. 2004, 50:263.
33. PubChem. http://pubchem.ncbi.nlm.nih.gov/.
34. Racis S.P., Plescia O.J., Geller H.M., Schaffner C.P. Comparative toxicities of amphotericin B and its monomethyl ester derivative on glial cells in culture. Antimicrob. Agents Chemother. 1990, 34:1360-1365.
35. Racke M.K., Gocke A.R., Muir M., Diab A., Drew P.D., Lovett-Racke A.E. Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J. Nutr. 2006, 136:700-703.
36. Ramamurthy S., Mir F., Gould R.M., Le Breton G.C. Characterization of thromboxane A2 receptor signaling in developing rat oligodendrocytes: nuclear receptor localization and stimulation of myelin basic protein expression. J. Neurosci. Res. 2006, 84:1402-1414.
37. Roth A.D., Leisewitz A.V., Jung J.E., Cassina P., Barbeito L., Inestrosa N.C., Bronfman M. PPAR gamma activators induce growth arrest and process extension in B12 oligodendrocyte-like cells and terminal differentiation of cultured oligodendrocytes. J. Neurosci. Res. 2003, 72:425-435.
38. Saito M., Iimori Y., Kamoshita S., Yanagisawa M., Sakakihara Y. Effects of peroxisomal beta-oxidation antagonist on 2′,3′-cyclic-nucleotide 3′-phosphohydrolase, membrane lipid compositions, and membrane fluidity in C-6 glial cells. Biochim. Biophys. Acta 1995, 1235:178-182.
39. Sakamoto H., Ukena K., Tsutsui K. Activity and localization of 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4-isomerase in the zebrafish central nervous system. J. Comp. Neurol. 2001, 439:291-305.
40. Saluja I., Granneman J.G., Skoff R.P. PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 2001, 33:191-204.
41. Schumacher M., Guennoun R., Robert F., Carelli C., Gago N., Ghoumari A., Gonzalez Deniselle M.C., Gonzalez S.L., Ibanez C., Labombarda F., Coirini H., Baulieu E.E., De Nicola A.F. Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination. Growth Horm IGF Res 2004, 14(Suppl. A):S18-S33.
42. SciFinder. SciFinder. http://www.cas.org/products/scifindr/.
43. Shin J., Park H.C., Topczewska J.M., Mawdsley D.J., Appel B. Neural cell fate analysis in zebrafish using olig2 BAC transgenics. Methods Cell Sci. 2003, 25:7-14.
44. Sim F.J., Lang J.K., Ali T.A., Roy N.S., Vates G.E., Pilcher W.H., Goldman S.A. Statin treatment of adult human glial progenitors induces PPAR gamma-mediated oligodendrocytic differentiation. Glia 2008, 56:954-962.
45. Sommer N., Loschmann P.A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmuller A., Fontana A., et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1995, 1:244-248.
46. Sperber B.R., Boyle-Walsh E.A., Engleka M.J., Gadue P., Peterson A.C., Stein P.L., Scherer S.S., McMorris F.A. A unique role for Fyn in CNS myelination. J. Neurosci. 2001, 21:2039-2047.
47. Sundararajan S., Jiang Q., Heneka M., Landreth G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem. Int. 2006, 49:136-144.
48. Tang H., Zhao Z.J., Huang X.Y., Landon E.J., Inagami T. Fyn kinase-directed activation of SH2 domain-containing protein-tyrosine phosphatase SHP-2 by Gi protein-coupled receptors in Madin-Darby canine kidney cells. J. Biol. Chem. 1999, 274:12401-12407.
49. Tobinick E.L. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009, 22:119.
50. Umemori H., Kadowaki Y., Hirosawa K., Yoshida Y., Hironaka K., Okano H., Yamamoto T. Stimulation of myelin basic protein gene transcription by Fyn tyrosine kinase for myelination. J. Neurosci. 1999, 19:1393-1397.
51. Van den Branden C., Leeman J., Dacremont G., Collumbien R., Roels F. Experimental inhibition of peroxisomal beta-oxidation in rats: influence on brain myelination. Glia 1990, 3:458-463.
52. Wang Z., Colognato H., Ffrench-Constant C. Contrasting effects of mitogenic growth factors on myelination in neuron-oligodendrocyte co-cultures. Glia 2007, 55:537-545.
53. Westerfield M. The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio) 2000, University of Oregon Press, Eugene.
54. White R., Gonsior C., Kramer-Albers E.M., Stohr N., Huttelmaier S., Trotter J. Activation of oligodendroglial Fyn kinase enhances translation of mRNAs transported in hnRNP A2-dependent RNA granules. J. Cell Biol. 2008, 181:579-586.
55. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., Chang Z., Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006, 34:D668-D672.
56. Wishart D.S., Knox C., Guo A.C., Cheng D., Shrivastava S., Tzur D., Gautam B., Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008, 36:D901-D906.
57. Wolkenstein P.E., Roujeau J.C., Revuz J. Drug-induced toxic epidermal necrolysis. Clin. Dermatol. 1998, 16:399-408.
58. Xu J., Storer P.D., Chavis J.A., Racke M.K., Drew P.D. Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J. Neurosci. Res. 2005, 81:403-411.
59. Xu J., Chavis J.A., Racke M.K., Drew P.D. Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J. Neuroimmunol. 2006, 176:95-105.
60. Zhao C., Fancy S.P., Kotter M.R., Li W.W., Franklin R.J.M. Mechanisms of CNS remyelination - the key to therapeutic advances. J. Neurol. Sci. 2005, 233:87-91.
61. Zon L.I., Peterson R.T. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 2005, 4:35-44.